Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
08:00 - 08:50 50 mins
Registration and Morning Coffee
08:50 - 09:00 10 mins
Cell Therapy Manufacturing Asia
Chairperson's Opening Remarks
  • Christopher Bravery - Director, Consulting on Advanced Biologicals Ltd., Member, ISCT EU Legal and Regulatory Affairs Committee, UK
more
09:00 - 09:35 35 mins
Cell Therapy Manufacturing Asia
Challenges and opportunities for cell Therapy in Asia
  • Mickey Koh - Director-Stem Cell Transplantation Consultant Haematologist/Hon Senior Lecturer, St George’s Hospital and Medical School, UK, Program and Medical Director Cell Therapy Facility Health Sciences Authority, Singapore
more
09:35 - 10:10 35 mins
Cell Therapy Manufacturing Asia
Chimeric Antigen Receptor T-Cell therapies for Solid Tumors
  • Jan Joseph Melenhorst - Director, Product Development & Correlative Sciences laboratories (PDCS), Adjunct Associate Professor, Center for Cellular Immunotherapies, University of Pennsylvania, USA
more

Progress in chimeric antigen receptor T (CAR T) cell therapies for hematopoietic malignancies has been stunning over the past decade, and solid tumors are only now catching up. One of the major challenges in the treatment of solid tumors with CAR T cells is the relative paucity of antigens selectively, let alone uniquely expressed by these cancers. In my talk I will briefly describe the development of the field, with an emphasis on how CAR T cell therapies have been evaluated in solid tumors, the antigens targeted; reasons why success has not been dramatic yet, and what the near future holds.

10:10 - 10:40 30 mins
Cell Therapy Manufacturing Asia
Discussion panel: Strategies for the successful commercialisation of cell therapies
  • Jan Joseph Melenhorst - Director, Product Development & Correlative Sciences laboratories (PDCS), Adjunct Associate Professor, Center for Cellular Immunotherapies, University of Pennsylvania, USA
  • Mickey Koh - Director-Stem Cell Transplantation Consultant Haematologist/Hon Senior Lecturer, St George’s Hospital and Medical School, UK, Program and Medical Director Cell Therapy Facility Health Sciences Authority, Singapore
more
  • What can the EU/US learn from Japan and visa versa
  • What have been successes and failures in the region
  • Strategies for navigating the Asian market with regards to commercialisation
  • What are the biggest challenges when working in the region?
  • Reimbursement and risk management strategies
10:40 - 11:15 35 mins
Morning Coffee and Networking
11:15 - 11:50 35 mins
Cell Therapy Manufacturing Asia
Allogeneic Stem Cell Bioprocesses for Mesenchymal and Pluripotent Stem Cells Manufacturing
  • Steve Oh - Director Stem Cell Bioprocessing & Institute Professor,, A*Star, Singapore
more
  • Reprogramming & selecting human induced pluripotent stem cells on microcarriers
  • Integrated Stem Cell Bioprocesses to make red blood cells
  • Biodegradable microcarriers for stem cell production and tissue implantation
  • New assays of cell quality and potency



11:50 - 12:25 35 mins
Cell Therapy Manufacturing Asia
Smart Cell Processing: Future of Cell Production
  • Shin Kawamata - Director, Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (FBRI), Japan
more

We have been developing an automated closed-cell culturing system using in-process monitoring. This system guarantees the quality of the cell products during processing by applying process analytical technology (PAT). Also, through data integration system in SCP, we can analyze trends of operations and QC test data of the products in process. SCP System is revolutionizing the current outdated and costly cell manufacturing approach and bringing breakthroughs to the medical field. In this session, we are introducing SCP System as a new cell manufacturing method focusing on industrializing and commercializing cell production for the generations to come

12:25 - 12:45 20 mins
Cell Therapy Manufacturing Asia
Automated manufacturing of cell- and gene therapies (CGT) at commercial scale
  • Hermann Bohnenkamp - VP Business Development APAC, Miltenyi Biotec, Germany
more
  • Control strategies for cell and gene therapies
  • Sourcing GMP ancillary / raw materials
  • Manufacturing process
  • In-process control (IPC) and quality control (QC)
  • Considerations of a fully automated cell manufacturing process
  • Case study: Decentralized manufacturing of CAR T cells using a fully-automated and closed system

12:45 - 13:15 30 mins
Cell Therapy Manufacturing Asia
Automation Expert Panel
  • Masahiro Kino-Oka - Professor, Department of Biotechnology, Graduate School of Engineering Osaka University, Japan
  • Shin Kawamata - Director, Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation (FBRI), Japan
  • Steve Oh - Director Stem Cell Bioprocessing & Institute Professor,, A*Star, Singapore
  • Toshihiko Hatanaka - Manager, GE Healthcare Life Sciences, Japan
  • Hermann Bohnenkamp - VP Business Development APAC, Miltenyi Biotec, Germany
more

Informa is looking for 5 speakers to join our expert led discussion panel to talk on the below topics:

  • Case studies/feedback on closed systems in general
  • Is there a need to have closed systems in clean rooms?
  • Process automated sampling
  • What can we learn from automation for MAbs?
  • How do you make thinks connectable between different devices?
  • Automation linked to cost of goods
13:15 - 14:25 70 mins
Lunch and Networking
14:25 - 15:00 35 mins
Cell Therapy Manufacturing Asia
3D suspension culture for scalable cultivation of pluripotent stem cells
  • Katsuhisa Matsuura - Associate Professor, Department of Cardiology, Tokyo Women's Medical University, Japan
more
15:00 - 15:30 30 mins
Cell Therapy Manufacturing Asia
Scale up of pluripotent stem cell cultivation and differentiation in a novel single-use bioreactor system
  • Brian Lee - President, PBS Biotech Inc.
more

Using single-use bioreactors to grow and differentiate pluripotent stem cells (PSCs) such as embryonic stem cells or induced pluripotent stem cells is considered a viable option for scale up of stem cell manufacturing process to commercial scale. PSCs are anchorage-dependent, and grow as aggregates or on microcarriers in a suspension culture, which makes them to be more susceptible to hydrodynamic shear stress compared to suspended single cells. Conventional stirred-type bioreactors with horizontal impellers require high agitation speeds and power inputs in order to fully suspend cell aggregates, which can negatively affect not only cell growth but also subsequent directed-differentiation in ways that may reduce cell growth rate, final product yield, quality, and potency. This problem becomes worse as bioreactor vessel size increases and is a key challenge for achieving satisfactory cell growth and differentiation outcomes for PSCs in bioreactors. A novel, single-use bioreactor system using Vertical-WheelTM technology has recently been introduced, which can achieve homogenous fluid mixing and uniform cell aggregate and microcarrier suspension using low agitation speeds and power inputs. The vertically-oriented mixing mechanism can consistently maintain a low shear environment across a full range of bioreactor working volumes and sizes, from 0.1 to 80 liters. The homogeneous distribution of turbulent energy dissipation rates inside a Vertical-Wheel bioreactor generates more uniform cell aggregates. In addition, the desired size of cell aggregates for optimal differentiation can be achieved by controlling agitation rate. Ultimately this can greatly increase the final yield of target cells, since the size of cell aggregates is critical for the kinetics and efficiency of directed differentiation. A homogeneous turbulent energy distribution and low hydrodynamic shear environment are unique benefits of Vertical-Wheel mixing and result in unparalleled scalability, from benchtop to commercial scale. Therefore, Vertical-Wheel bioreactor systems can be the ideal platform to develop robust manufacturing processes and scale up of shear-sensitive PSC products. These single-use Vertical-Wheel bioreactors have also demonstrated superior performance, compared to conventional stirred bioreactors, on the production of other cell therapy products including human mesenchymal stem cells and human chondrocytes grown on microcarriers. Results of Kolmogorov scale measurements, growth of anchorage-dependent cells, and differentiation yields of PSC’s in various sizes of Vertical-Wheel bioreactors will be discussed in this presentation.

15:30 - 16:00 30 mins
Afternoon Coffee Break
16:00 - 16:35 35 mins
Cell Therapy Manufacturing Asia
Cell manufacturing based on flexible modular platform
  • Masahiro Kino-Oka - Professor, Department of Biotechnology, Graduate School of Engineering Osaka University, Japan
more

Expansion cell culture, which is the most critical steps to realize the transplant of cells or tissues for cell therapy or regenerative medicine, respectively, will be done in terms of safety and cost-saving under the aseptic environment in the cell processing facility (CPF). The cell processing isolator system can enable cell processing in a closed aseptic chamber, which may reduce equipment and maintenance/operation costs while providing a reliable aseptic environment. In case of autologous cell processing, the CPFs are expected to handle cells collected from a large number of patients, and some believe that isolators with a function to prevent cross-contamination may be advantageous in providing a more reliable aseptic environment compared with open operation in the facilities. A novel isolator system based on a flexible Modular Platform (fMP) was designed to realize that the individual modules can connect and disconnect flexibly with keeping the aseptic environment inside each module, applying the cell processing. In addition, as it is known that the serial processes for cell processing affect the quality of the cells, the machinery processes are conducted not only to maintain an aseptic environment but also to lead to process stability in CPF. Thus, our attempts are concluded to build an advanced culture system employing isolator technology, and the adaptation of the fMP in CPF will lead to easy installation of the new modules for production line addition and/or revision through the clinical phases as well as commercial production, which contributes to the reduction of production costs.

16:35 - 17:10 35 mins
Cell Therapy Manufacturing Asia
Cost of goods calculations for cell therapy products
  • Kim Raineri - Vice President Operations, NIKON CeLL innovation Co., Ltd., Japan
more


  • Case study
17:10 - 17:15 5 mins
Cell Therapy Manufacturing Asia
Chairperson's Closing Remarks
17:15 - 19:15 120 mins
Networking Drinks and Evening Social Event